

5th International Symposium on Childhood, Adolescent, and Young Adult Hodgkin Lymphoma

October 19-21, 2023

Renasant Convention Center, Memphis, Tennessee



Scan to view event details or visit: stjude.org/iscayahl



Welcome

The **5th International Symposium on Childhood Adolescent, and Young Adult Hodgkin Lymphoma (ISCAYAHL)** will focus on updates on the main questions in the field of pediatric, adolescent and young adult (AYA) Hodgkin lymphoma (HL) such as clinical trial portfolios from around the world, novel therapeutics, biomarkers, and novel imaging and survivorship outcomes in pediatric HL. The goal of this conference is to provide a platform to share work from global collaborations and to form new ones.

There will be both oral and poster sessions, as well as accompanying awards:

- Achievement Award in the Field of Pediatric Lymphoma
- Poster awards

There are many opportunities to network and join in the symposium action:

- Learn: Check out the ISCAYAHL 2023 website (QR code below) to view the digital version of the symposium booklet.
- **Discover:** Enjoy appetizers and cocktails while you view symposium posters and network in the afternoon on Thursday, October 19 and Friday, October 20.
- **Connect:** Engage with fellow international lymphoma enthusiasts at the symposium dinner on Friday, October 20 at the Renasant Convention Center. *Dinner is included with registration*.
- **Get Active:** Start your weekend with some movement and reflection. A yoga class will be held free of charge on Saturday, October 21. All skill levels are encouraged to attend. Yoga mats will be provided.
- **Explore:** Conclude your ISCAYAHL 2023 experience with a tour of the St. Jude campus starting at 1:30pm on Saturday, October 21.



Scan to view event details or visit: stjude.org/iscayahl

Symposium Co-Chairs



Jamie E. Flerlage, MD, MS University of Rochester, NY USA



Christine Mauz-Körholz, MD Justus-Liebig-University of Gießen; EuroNet-PHL Group Germany



Sharon M. Castellino, MD, MSc Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta; Emory University School of Medicine USA

Scientific Committee



Auke Beishuizen, MD, PhD Princess Máxima Centre for Pediatric Oncology The Netherlands



Catherine M Bollard, MBChB, MD Children's National and George Washington University USA



Andreas Bräuninger, PhD Universitätsklinikum Gießen Germany



Stephen Daw, MD University College Hospital in London United Kingdom



Mario J A de Paula, MSc Hospital de Amor Brazil



Karin Dieckmann, MD Medical University of Vienna Austria



Matthew J Ehrhardt, MD, MS St. Jude Children's Research Hospital USA



Andy Evens, DO, MBA, MSc Rutgers Cancer Institute of New Jersey USA



Angela Feraco, MD, MMSc Dana-Farber Cancer Institute USA



Stefan Gattenlöhner, MD Justus-Liebig-University Gießen Germany



Lisa Giulino Roth, MD Weill Cornell Medical College USA



Brad Hoppe, MD, MPH, FASTRO Mayo Clinic, FL USA



Melissa M Hudson, MD St. Jude Children's Research Hospital USA



Kara Kelly, MD Roswell Park Comprehensive Cancer Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences USA



Tomasz Klekawka, MD Jagiellonian University Medical College Poland

Scientific Committee (cont.)



Regine Kluge, MD University Hospital of Leipzig Germany



Dieter Körholz, MD Justus-Liebig-University Gießen Germany



Judith Landman-Parker, MD Armand-Trousseau Sorbonne University Hospital France



Thierry Leblanc, MD Hôpital Universitaire Robert Debré France



Megan Lim, MD, PhD Memorial Sloan Kettering Cancer Center USA



Andrea Lo, MD, MPH BC Cancer Vancouver Centre Canada



John T Lucas Jr., MD, MS St. Jude Children's Research Hospital USA



Kathleen M. McCarten, MD IROCRI (Imaging and Radiation Oncology Core-Rhode Island USA



Marius Rohde, Dr.
Justus Liebig University
Gießen / University
Hospital Gießen
Germany



Jennifer Seelisch, MD, MSc Children's Hospital London Health Sciences Centre, Ontario, Canada Canada



Christian Steidl, MD BC Cancer Canada



Dietrich Stoevesandt, Dr. Med, PhD University Hospital Halle Germany



Leanne Super, MBBS, FRACP Children's Cancer Centre, Monash Children's Hospital/ Royal Children's Hospital

Australia



Anke van den Berg, Prof. Dr. Universitair Medisch Centrum Groningen (UMCG) The Netherlands



David Veron, MD, PhD Hospital Universitario Austral Argentina

Symposium Faculty

Sharon M. Castellino, MD, MSc	Emory University School of Medicine, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta	USA
Alexander Claviez, MD	Children's Hospital, University of Magdeburg	Germany
Pedro A de Alarcon, MD	University of Illinois College of Medicine Peoria and St. Jude Children's Research Hospital	USA
Mario J A de Paula, MSc	Hospital de Amor	Brazil
Karin Dieckmann, MD	Medical University of Vienna	Austria
Adam DuVall, MD, MPH	University of Chicago	USA
Matthew J Ehrhardt, MD, MS	St. Jude Children's Research Hospital	USA
Angela M. Feraco, MD, MMSc	Dana-Farber Cancer Institute	USA
Jamie E Flerlage, MD, MS	University of Rochester, NY	USA
Chris Forlenza, MD	Memorial Sloan Kettering Cancer Center	USA
Lisa Giulino Roth, MD	Weill Cornell Medical College	USA
Richard T. Hoppe, MD	Stanford University	USA
George Hucks, MD	Lineberger Comprehensive Cancer Center, University of North Carolina	USA
Kara Kelly, MD	Roswell Park Comprehensive Cancer Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences	USA
Lars Kurch, Dr. Med., MaHM	University Hospital Leipzig	Germany
John T. Lucas Jr., MD, MS	St. Jude Children's Research Hospital	USA
Raymond Mailhot Vega, MD MPH	University of Florida	USA

Symposium Faculty (cont.)

Ajay Major, MD, MBA	University of Colorado School of Medicine	USA
Maurizio Mascarin, MD	CRO Centro di Riferimento Oncologico, IRCCS	Italy
Christine Mauz-Körholz, MD	Justus-Liebig-University of Gießen; EuroNet-PHL Group	Germany
Kathleen M. McCarten, MD	IROCRI (Imaging and Radiation Oncololgy Core- Rhode Island	USA
Jennifer Seelisch, MD, MSc	Children's Hospital London Health Sciences Centre	Canada
Mathieu Simonin, MD	Hôpital Armand-Trousseau	France
Dietrich Stoevesandt, Dr. Med, PhD	University Hospital Halle	Germany
Leanne Super, MBBS, FRACP	Children's Cancer Centre, Monash Children's Hospital/ Royal Children's Hospital	Australia
Anke van den Berg, Prof.Dr.	Universitair Medisch Centrum Groningen (UMCG)	The Netherlands
Margreet Veening, MD, PhD	Princess Máxima Center for Pediatric Oncology	The Netherlands

Agenda At-A-Glance

	Thursday, October 19, 2023		
8:00-9:30 AM	Survivorship		
	BREAK		
9:45 AM-12:00 PM	Clinical Trials Updates		
12:00-1:00 PM	LUNCH 12:15 Survivor Panel Discussion		
1:00-2:30 PM	Radiation Oncology / Imaging		
	BREAK		
2:45-4:15 PM	SEARCH for CAYAHL		
	BREAK		
4:30-5:15 PM	Poster Pitch Day 1		
	BREAK		
5:30-6:15 PM	Keynote Lecture Cocktails and appetizers (reception to continue after)		
	Friday, October 20, 2023		
8:00-8:45 AM	Meet the Experts		
	BREAK		
9:00-10:15 AM	Health Outcomes		
	BREAK		
10:30 AM-12:00 PM	Novel Therapeutics & Cellular Therapies		
12:00-1:00 PM	LUNCH		
1:00-3:00 PM	Translational Biology		
	BREAK		
3:15-5:00 PM	Global Initiatives / Global Trials		
	BREAK		
5:15-6:00 PM	Poster Pitch Day 2 Cocktails and appetizers (reception to continue after)		
7:00 PM	Symposium Dinner		
	Saturday, October 21, 2023		
7:00-8:00 AM	Yoga		
9:00-10:30 AM	Adolescents & Young Adults		
	BREAK		
10:45 AM-12:15 PM	Relapse Treatment & Challenging Cases		
12:15 PM	Closing & Awards		
1:30 PM	St. Jude Tour		

Wednesday, October 18, 2023 (Closed Meetings)

11:00am	Registration Opens	
1:00 - 4:00 pm	Parallel Session Children's Oncology Group European Network for Paediatric Hodgkin Lymphoma Pediatric Hodgkin Consortium	Sharon M. Castellino, MD, MSc Christine Mauz-Körholz, MD Jamie E. Flerlage, MD, MS
4:00 - 5:00 pm	Coming Together	
5:00 - 6:00 pm	Networking Reception Wine, cheese, and appetizers	

Thursday, October 19, 2023

7:30 am	Registration Opens	
8:00 - 8:05 am	Welcome & Opening Remarks	Jamie E. Flerlage, MD, MS Christine Mauz-Körholz, MD Sharon M. Castellino, MD, MSc
8:05 - 9:30 am	Survivorship	Session Co-Chairs: Margreet Veening, MD, PhD & Matthew J. Ehrhardt, MD, MS
	Invited Presenter(s) Dutch Outpatient Clinics for Late Effects (BETER)	Annelies Nijdam, PhD Netherlands Cancer Institute, The Netherlands
	Gonadal function and fertility preservation in pediatric patients with Hodgkin lymphoma treated according to the EURONET-PHL-C2 Protocol: the fertility add-on study	Katja Drechsel, MD Princess Máxima Center for Pediatric Oncology and Amsterdam UMC location VUmc, The Netherlands
	Cognitive and Sleep Problems in Hodgkin Lymphoma	Belinda Mandrell, PhD,RN, FAAN St. Jude Children's Research Hospital, USA
	Oral Presenter(s) Hypertension and Related-Disorders are Prevalent in Hodgkin Lymphoma Patients Identified from the EPIC Cosmos System	John Mariano, MD University of Rochester Medical Center, USA

Thursday, October 19, 2023 (cont.)

9:45 am - 12:00 pm

Clinical Trials Updates

Session Co-Chairs:

Kara Kelly, MD & Tomasz Klekawka, MD

Invited Presenter(s)

European Network for Paediatric Hodgkin Lymphoma Christine Mauz-Körholz, MD Justus-Liebig-University of Gießen; EuroNet-PHL Group, Germany

Children's Oncology Group

Sharon M. Castellino, MD, MSc Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta; Emory University School of Medicine, USA

Pediatric Hodgkin Consortium

Jamie E Flerlage, MD, MS University of Rochester, NY, USA

Oral Presenter(s)

Evaluating CHIPS Validation in Pediatric High Risk Hodgkin Lymphoma Treated on AHOD1331

Jennifer Belsky, DO, MS Riley Children's Hospital, USA

Validation of Childhood Hodgkin International Prognostic Score (CHIPS) for Predicting Event-Free Survival in Intermediate and High-risk Hodgkin Lymphoma Lianna Marks, MD Stanford University, USA

Patterns of presentation and outcomes in Stage IV Hodgkin lymphoma: A report from the Children's Oncology Group (COG) AHOD1331 trial

Angela Punnett, MD, FRCPC The Hospital for Sick Children (SickKids), Canada

Pembrolizumab in children and young adults with classical Hodgkin lymphoma with slow early response to front-line chemotherapy: phase 2 KEYNOTE-667

Christine Mauz-Körholz, MD Justus-Liebig-University of Gießen; EuroNet-PHL Group, Germany

Thursday, October 19, 2023 (cont.)

12:00 - 1:00 pm Lunch

12:15 - 1:00 pm **Survivor Panel Discussion** Moderator:

Valerie Crabtree, PhD

1:00 - 2:30 pm Radiation Oncology/Imaging **Session Co-Chairs:**

Karin Dieckmann, MD & Raymond

University of Colorado Denver, USA

Mailhot Vega, MD, MPH

Sarah Milgrom, MD

Invited Presenter(s)

Evolution in radiotherapy for pediatric Hodgkin Brad Hoppe, MD, MPH, FASTRO lymphoma, based on relapse patterns of the past Mayo Clinic, FL, USA

The Role of PET Volumetrics in Pediatric Hodgkin Lymphoma

Oral Presenter(s)

Resource-Adapted Global Radiation Therapy Bilal Mazhar Qureshi, MD, MBBS, FCPS Recommendations Through the Adapted The Aga Khan University Hospital, Pakistan Resource and Implementation Application (ARIA)

Radiotherapy utilization and outcomes on a contemporary trial for pediatric high-risk

Adapted Management Guideline (AMG) for

Hodgkin lymphoma study

Hodgkin Lymphoma (HL)

Raymond Mailhot Vega, MD, MPH University of Florida, USA

FDG PET/CT in pediatric Hodgkin Lymphoma: initial results of an Italian prospective study

Egesta Lopci, MD, PhD Centro di Riferimento Oncologico, Italy

Thursday, October 19, 2023 (cont.)

2:45 - 4:15 pm	SEARCH for CAYAHL	Session Co-Chairs: Jennifer Seelisch, MD, MSc & Lars Kurch, Dr. Med, MaHM	
	Invited Presenter(s) SEARCH for CAYAHL Introduction	Jennifer Seelisch, MD, MSc Children's Hospital London Health Sciences Centre, Canada Lars Kurch, Dr. Med, MaHM University Hospital Leipzig, Germany	
	SEARCH for CAYAHL Atlas	Dietrich Stoevesandt, Dr. Med, PhD University Hospital Halle, Germany	
	E-lesions in Hodgkin lymphoma	Auke Beishuizen, MD, PhD Princess Máxima Centre for Pediatric Oncology, The Netherlands	
	Definition of Lung Involvement	Jennifer Seelisch, MD, MSc Children's Hospital London Health Sciences Centre, Canada	
		Jonas Steglich, MD University Hospital Halle, Germany	
	CNS Involvement in Pediatric Hodgkin Lymphoma: a Comprehensive Retrospective Analysis from SEARCH for CAYAHL	Kathleen M. McCarten, MD IROCRI (Imaging and Radiation Oncology Core-Rhode Island, USA	
	Oral Presenter(s) Towards Incorporation of Pediatric Specific Criteria in the Revised Lugano Classification of Hodgkin Lymphoma Staging and Response: Report from the ICML Pediatric Subcommittee	Kara Kelly, MD Roswell Park Comprehensive Cancer Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, USA	
4:30 - 5:15 pm	Poster Pitch Day 1	Moderator: John T. Lucas Jr., MD, MS	
5:30 - 6:15 pm	Keynote lecture: Hodgkin's Disease – the first 150 years!	Richard T. Hoppe, MD Stanford University, USA	
6:30 pm	Poster and Networking Reception Cocktails and appetizers available		

Friday, October 20, 2023

7:30 am	Registration Opens	
8:00 - 8:05 am	Meet the Experts: Interactive Case Discussion	Session Co-Chairs: Kathleen M. McCarten, MD & Dietrich Stoevesandt, Dr. Med, PhD
9:00 - 10:15 am	Health Outcomes	Session Co-Chairs: Angela Feraco, MD, MMSc & Ajay Major, MD, MBA
	Invited Presenter(s) A Foot in the Door to Storming the Barn: The evolution of patient-reported outcomes in Hodgkin lymphoma clinical trials	Susan Parsons, MD, MRP Tufts Medical Center, USA
	Trends in Excess Deaths Among Survivors of Adolescent and Young Adult Hodgkin Lymphoma	AnnaLynn Williams, PhD University of Rochester Medical Center, USA
	Oral Presenter(s) Investigating Diagnosis and Management of Chemotherapy-Induced Peripheral Neuropathy: Current Practice Patterns of Pediatric and Medical Oncologists	Jennifer Belsky, DO, MS Riley Children's Hospital, USA
	The role of protocol-stipulated dose modification in the Children's Oncology Group AHOD1331 study to manage chemotherapy-induced peripheral neuropathy	Mallorie Heneghan, MD, MS University of Utah Health, USA
	Association of health insurance continuity with cancer stage and survival among US children, adolescents, and young adults newly diagnosed with Hodgkin lymphoma	Sharon M. Castellino, MD, MSc Emory University School of Medicine, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, USA
	Skeletal Muscle Index and Early Response in Pediatric Hodgkin Lymphoma (HL): A Children's Oncology Group (COG) Study AHOD0031 and AHOD0831 Report	Aman Wadhwa, MD, MSPH University of Alabama at Birmingham, USA

Friday, October 20, 2023 (cont.)

Hodgkin lymphoma

10:30 am - 12:00 pm	Novel Therapeutics & Cellular Therapies	Session Co-Chairs: George Hucks, MD & Mathieu Simonin, MD
	Invited Presenter(s) CD30 CAR-T Cells in Hodgkin Lymphoma	Natalie Grover, MD Lineberger Comprehensive Cancer Center, University of North Carolina, USA
	Response-adapted therapy (tx) with nivolumab plus brentuximab vedotin (nivo + BV) without autologous hematopoietic cell transplantation (auto-HCT) in children, adolescents, and young adults (CAYA) with low-risk relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL): CheckMate 744.	Paul Harker-Murray, MD, PhD Medical College of Wisconsin, USA
	Overcoming resistance to PD-1 blockade in Hodgkin Lymphoma	Alex F. Herrera, MD City of Hope Medical Center, USA
	Oral Presenter(s) CD70 immunohistochemical expression in classic Hodgkin lymphoma (CHL): An argument for the use of targeted anti-CD70 therapy in pediatric CHL; A single institutional experience	Mahsa Khanlari, MD St. Jude Children's Research Hospital, USA
12:00 - 1:00 pm	Lunch	
1:00 - 3:00 pm	Translational Biology	Session Co-Chairs: Lisa Giulino Roth, MD & Anke van den Berg, Prof.Dr.
•	Invited Presenter(s) Whole genome sequencing of Hodgkin-Reed/	Enrico Tiacci, MD

Translational Biology	Session Co-Chairs: Lisa Giulino Roth, MD & Anke van den Berg, Prof.Dr.
Invited Presenter(s) Whole genome sequencing of Hodgkin-Reed/ Sternberg cells	Enrico Tiacci, MD University and Hospital of Perugia, Italy
Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells	Lisa Giulino Roth, MD Weill Cornell Medical College, USA
Whole exome sequencing of ctDNA of pediatric Hodgkin lymphoma	Theresa Jox, Dr. Rer. Nat. UKGM and Justus-Liebig University, Germany
Spatially resolved biology in classic	Tomohiro Aoki, MD, PhD

Princess Margaret Cancer Centre, Canada

Friday, October 20, 2023 (cont.)

1:00 - 3:00 pm

Translational Biology (cont.)

Oral Presenter(s)

Circulating cell-free DNA in classical Hodgkin lymphoma in children adolescents and young adults: Preliminary results from the HOLY study, a French ancillary study of EuroNet PHL-C2 protocol Mathieu Simonin, MD Hôpital Armand-Trousseau, France

Distinct Hodgkin lymphoma subtypes identified by noninvasive genomic profiling

Ragini Adams, MD Stanford University, USA

3:15 - 5:00 pm

Global Initiatives/Global Trials

Session Co-Chairs:

Pedro A de Alarcon, MD & Mario J A de Paula, MSc

Invited Presenter(s)

GLOW: NLPHL Prospective Trial in Development

Burton Appel, MD, MBA

Hackensack University Medical Center, USA

ARIA Process and Implementation

Miguel Bonilla, MD

St. Jude Global | ARIA Guideline

Initiative, USA

Classical Hodgkin Lymphoma in India

Amita Mahajan, MD, MRCPCH & CCST Indraprastha Apollo Hospital, India

Classical Hodgkin Lymphoma in Latin America

Ana Yéssika Gamboa-Chaves, MD Hospital Nacional de Niños, Costa Rica

Classical Hodgkin Lymphoma in Africa

Daniel Hailu, MD

Addis Ababa University, Ethiopia

Advancing immunotherapy for Hodgkin lymphoma

Scott Charles Howard, MD, MSc San Joan de Deu Hospital, Spain

Oral Presenter(s)

Brazilian Results of a Latin American Guide to Treat Children and Adolescents with Classical Hodgkin Lymphoma: An Effort to Harmonize Nationwide Care Ana Rosa Costa, MD, PhD

Hospital de Cancer de Barretos, Brazil

Friday, October 20, 2023 (cont.)

5:15 - 6:00 pm Poster Pitch Day 2 Moderator:

Leanne Super, MBBS, FRACP

Poster and Networking Reception 6:00pm

Cocktails and appetizers available

7:00pm **Symposium Dinner**

Renasant Convention Center

Saturday, October 21, 2023

7:00 - 8:00 am Kim Proctor, Yoga Instructor Yoga

9:00 - 10:30 am **Adolescents & Young Adults** Session Co-Chairs:

Maurizio Mascarin, MD & Adam DuVall, MD,

MPH

Invited Presenter(s)

Mats will be provided

Assessing and Addressing Sexual Health Sage Bolte, PhD, LCSW, CST needs of AYA Inova Health System, USA

Tara O. Henderson, MD, MPH Association of Changes in Hodgkin Lymphoma Therapy Over 3 Decades with Risk of Subsequent University of Chicago, USA

Breast Cancer

Premature Ovarian Insufficiency in AYAs with Maria Velez, MD, PhD, FRCSC Hodgkin Lymphoma Queen's University, Canada

Kieron M. Dunleavy, MD

Challenges in the Treatment of Lymphoma MedStar Georgetown University Hospital, **USA**

in Pregnancy

18

Saturday, October 21, 2023 (cont.)

10:45 am - 12:15 pm

Relapse Treatment & Challenging Cases

Session Co-Chairs:

Chris Forlenza, MD & Alexander Claviez, MD

Invited Presenter(s)

Treatment of NLPHL

Jamie E Flerlage, MD, MS University of Rochester, NY, USA

Oral Presenter(s)

Case report: Rare combination of Hodgkin Lymphoma and Hypoplastic Left Heart Syndrome- tailoring treatment to medical comorbidities to achieve excellent response while minimising unwanted toxicities Leanne Super, MBBS, FRACP Children's Cancer Centre, Monash Children's Hospital/ Royal Children's Hospital, Australia

Invited Presenter(s)

Pediatric Approaches Towards Firstline Salvage Therapies for Initial Relapse/Refractory Hodgkin Lymphoma Chris Forlenza, MD Memorial Sloan Kettering Cancer Center, USA

Options for consolidation in relapsed/refractory HL outside HDT/ASCT

Maurizio Mascarin, MD CRO Centro di Riferimento Oncologico, IRCCS, Italy

Challenging AYA cases

Andy Evens, DO, MBA, MSc Rutgers Cancer Institute of New Jersey, USA

Kara Kelly, MD

Roswell Park Comprehensive Cancer Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, USA

12:15 pm Closing & Awards

1:30 - 2:30 pm St. Jude Children's Research Hospital Tour

Poster Presentations

The **5th International Symposium on Childhood Adolescent, and Young Adult Hodgkin Lymphoma** is excited to showcase this year's poster presentations. Discover posters in person at the Renasant Convention Center.

Poster Pitch Day 1

Thursday, October 19

Moderator: John T. Lucas Jr., MD, MS

	Presenter	Title
1	Caitlyn Duffy	Adapted Resource and Implementation Application (ARIA) Adapted Management Guideline (AMG): An Approach to Beta Testing for Hodgkin Lymphoma
2	Hesham Elhalawani	Dosimetric benefits of MR-guided radiotherapy in pediatric mediastinal Hodgkin Lymphoma: A case report
3	Suzi Birz	Data Collaborations Accelerate Pediatric Hodgkin Lymphoma Research Through NODAL
4	Angela Feraco	Dose-dense chemotherapy for low-risk pediatric Hodgkin lymphoma enables de-escalation of radiotherapy: a report from the Pediatric Hodgkin Consortium
5	Paul Harker-Murray	Response-adapted therapy (tx) with nivolumab plus brentuximab vedotin (nivo + BV) without autologous hematopoietic cell transplantation (auto-HCT) in children, adolescents, and young adults (CAYA) with low-risk relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL): CheckMate 744.
6	Tara Henderson	AHOD2131: A Randomized Phase 3 Interim Response-Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma, An Intergroup NCTN Phase 3 Study
7	Lianna Marks	Positron Emission Tomography Response and Outcome in Low-Risk Nodular Lymphocyte Predominant Hodgkin Lymphoma in AHOD03P1 study
8	Irina Melnichenko	A decision tree analysis of pros and cons of upfront checkpoint inhibition in newly-diagnosed Hodgkin lymphoma
9	Dietrich Stoevesandt	An expert consensus on the definition of independent lymph node regions in pediatric Hodgkin lymphoma by the International Collaboration on Staging Evaluation and Response Criteria Harmonization (SEARCH) for Children, Adolescent, and Young Adult Hodgkin Lymphoma (CAYAHL)
10	Stephan Voss	Altered biodistribution of FDG in Pediatric Hodgkin Lymphoma after completion of high dose steroid therapy: A case series with important clinical implications

Poster Presentations (cont.)

Poster Pitch Day 2

Friday, October 20

Moderator: Leanne Super, MBBS, FRACP

	Presenter	Title
11	Rosa Angarano	Validation of a Gene Signature Based on the Composition of the Tumor Microenvironment for Risk Stratification of Pediatric Patients with Classic Hodgkin's Lymphoma
12	Tomohiro Aoki	The spatially resolved tumor microenvironment predicts treatment outcome in relapsed/refractory Hodgkin lymphoma
13	Valli De Re	HLA and chemokines influencing relapse risk in EBV-related Hodgkin's lymphoma in young patients treated with EuroNet-PHL-C2 protocol - AIEOP Group
14	Mallorie Heneghan	Inferior Outcomes for Young Adults Treated on Advanced Stage Clinical Trials: Report from the HoLISTIC Consortium
15	Reham Khedr	Prognostic Significance of PD1, PD-L1 Expression, Pathological Subtypes and Metabolic Activity on 18F-FDG PET/CT in Refractory/Relapsing Pediatric Hodgkin Lymphoma
16	Patricia Lein	ONECUT2 and endogenous retrovirus expression in Hodgkin lymphoma cells
17	Mariam Minasyan	Checkpoint inhibitor immunotherapy for relapsed Hodgkin's lymphoma in children and adolescents in Armenia
18	Tais Tavares Barlera	A rare form of Post-Transplantation Lymphoproliferative Disorder in a pediatric patient
19	Tais Tavares Barlera	PD-1 expression in children and adolescents with Classical Hodgkin Lymphoma
20	Luciana Vinti	Brentuximab Vedotin in combination with bendamustine in paediatric patients or young adults with relapsed or refractory Hodgkin Lymphoma: a real-world experience
21	AnnaLynn Williams	Health-related Quality of Life Trajectories among Patients with High Risk Pediatric Hodgkin Lymphoma treated on the Children's Oncology Group (COG) AHOD 1331 Study

Continuing Medical Education Information

Educational Objectives

After attending this educational conference, you should be able to:

- Develop standards of care for children, adolescents, and young adults (AYA) with Hodgkin lymphoma (HL) globally
- Review clinical science and trial advances for pediatric and AYA HL to harmonize future iterations of trial development
- Advance use of patient-reported outcomes in HL to improve personalized approaches to care
- · Utilize current state of survivorship research to inform therapeutic advances in HL

Please note that session objectives will be presented during the conference as appropriate.

Accreditation Statement



St. Jude Children's Research Hospital is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

St. Jude Children's Research Hospital designates this live activity for a maximum of 19.75 AMA PRA Category 1 $Credits^{TM}$. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

Evaluation and Claiming Credit

To claim AMA PRA Category 1 CreditTM or attendance credit for this activity, you must attend the sessions, complete the evaluation, and follow the instructions at the end of the evaluation to claim your credit and receive a certificate. The link to the evaluation will be sent to attendees after the close of the symposium.

If you have questions about claiming your CME or attendance certificate, please contact us at cme@stjude.org. The evaluation will be open until **January 20, 2024**; you will not be able to claim credit after the evaluation is closed.

Disclosure of Financial Relationships

All individuals in a position to control the content of this CME activity (such as faculty, presenters, and planners) were asked to complete a statement regarding all financial relationships between themselves and any ineligible company (defined by the ACCME as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients).

All relevant financial relationships are disclosed below and have been mitigated. No other speakers, planners, or other individuals with control over content have disclosed relevant financial relationships with ineligible companies.

Continuing Medical Education Information (cont.)

Name	Nature of Relationship	Company(ies)		
Catherine Bollard	Consultant fees	SOBI, Cabaletta Bio, Catamaran Bio, Mana Therapeutics,		
	Ownership interest	Neximmune, Repertoire Immune Medicines, Mana Therapeutics (relationship has ended), Cabaletta Bio, Catamaran Bio		
	Intellectual property	Mana Therapeutics, Cellmedica		
Andreas Bräuninger	Consultant fees	Astra Zeneca, Roche		
	Supported/contracted research	Merck		
Sharon M Castellino	Consultant fees	Bristol Myers Squibb		
	Supported/contracted research	SeaGen		
Kieron Michael Dunleavy	Consultant fees	Amgen, Astra Zeneca, Abbvie, Beigene, Bristol-Meyer Squibb, Cellectar, Kite, ONO		
	Supported/contracted research	ONO, Kymera, Genentech, Merck		
Caitlyn Duffy	Supported/contracted research	Amgen Foundation		
Andrew Evens	Advisory board or DSMB	Seattle Genetics, Incyte, Daiichi Sankyo, Epizyme, Novartis, and Pharmacyclics		
Jamie Flerlage	Supported/contracted research	Seagen Research Support		
Natalie Grover	Consultant fees	Seagen; BMS; Kite; ADC Therapeutics; Novartis; Caribou Biosciences; Genentech		
	Ownership interest	Sangamo Biosciences		
Alex Herrera	Consultant fees	Bristol Myers Squibb, Genentech, Merck, Seattle Genetics, AstraZeneca, Karyopharm, ADC Therapeutics, Takeda, Tubulis, Regeneron, Genmab, Pfizer, Caribou Biosciences, Adicet Bio, Abbvie, Allogene Therapeutics		
	Supported/contracted research	Bristol Myers Squibb, Genentech, Merck, Seattle Genetics, KiTE Pharma, Gilead Sciences, AstraZeneca, ADC Therapeutics		

Continuing Medical Education Information (cont.)

Bradford Hoppe	Scientific advisory committee	Merck (contracted through Children's Oncology Group)		
Scott Howard	Consultant fees, speaker's bureau	Jazz Pharma, BTG Pharma		
	Supported/contracted research	Jazz Pharma		
Tomasz Klekawka	Conference support	Novartis		
Judith Landman- Parker	Supported/contracted research	BMS, MSD, Astellas, Pfizer, Sanofi, GSK		
Thierry Leblanc	Honoraria, travel fees	BMS, MSD		
Megan Lim	Supported/contracted research	ThermoFisher		
Christine Mauz-Körholz	Supported/contracted research	MSD		
Susan Parsons, MD, MRP	Consultant fees	Seagen		
Lisa Roth	Consultant fees	Merck, Roche		
Christian Steidl	Consultant fees	Bayer		
	Supported/contracted research	Epizyme, Trillium		
	Sponsored travel	Elsai		
Enrico Tiacci	Consultant fees	Kite/Gilead, Deciphera, Innate Pharma		
	Supported/contracted research	Roche		


See you at the next ISCAYAHL!

We look forward to seeing you at the

6th International Symposium on Childhood Adolescent, and Young Adult

Hodgkin Lymphoma

Berlin, Germany 2025



Reed-Sternberg Cells

Watercolour study by **Katie Rose Thorne** painted during her treatment in 2009.

Notes

Notes			

International Symposium on



